All In Biotech

NDA 215935 · Calliditas

Tarpeyo

Budesonide · Oral · Corticosteroid

Accelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 15, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

46,292

32,716 serious, 3,173 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 21, 2026.

TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. TARPEYO is a corticosteroid indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. ( 1 )

Mechanism: Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. Mucosal B-cells present in the ileum, including the Peyer's patches, express glucocorticoid receptors and are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1) causing IgA nephropathy. Through their anti-inflammatory and immunosuppressive effects at the glucocorticoid receptor, corticosteroids can modulate B-cell numbers and activity. It has not been established to what extent TARPEYO's efficacy is mediated via...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2023 Supplement 3 · Efficacy · priority review OrphanLabelLetter
  • Dec 15, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Accelerated approvalOrphanLabelLetterReview
1 products under this application
  • TARPEYO · BUDESONIDE 4MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,153
  • off label use4,835
  • dyspnoea4,732
  • asthma3,639
  • fatigue3,216
  • headache2,841
  • diarrhoea2,581
  • condition aggravated2,572
  • nausea2,396
  • cough2,338
  • pneumonia2,300
  • wheezing2,033

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
2005220
2006195
2007197
2008282
2009292
2010320
2011533
2012736
2013782
2014978
20151,346
20161,591
20171,682
20182,259
20192,940
20203,524
20213,719
20224,585
20235,404
20245,618
20255,018
20263,933

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tarpeyo (Budesonide)

2024 spending

$38.3M

Beneficiaries

468

2,385 claims

Per beneficiary

$81,739

$138.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$2,522,852
2023$16,016,957
2024$38,253,796

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,119 on PubMed

Sponsor: Calliditas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.